Personalized mRNA cancer vaccine shows promise in extending life span in melanoma trial
Wednesday, August 19, 2026 6:57PM
Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.
Merck / Moderna
Copyright © 2026 KABC Television, LLC. All rights reserved.